PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

<p>Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/pds-biotech-reschedules-key-opinion-leader-roundtable-addressing-current-and-future-treatments-for-recurrent-metastatic-hpv-positive-hnscc-and-the-potential-application-of-pds0101/">PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>